What does it mean to evaluate a research peptide vendor?
Evaluating a vendor means testing whether the material a supplier ships matches what the supplier says it ships, and whether the supplier can show evidence for that claim. It is a verification exercise. A peptide listing is a set of claims: an identity, a purity figure, a quantity, a storage condition. Evaluation separates the claims that have documentary support from those that are simply asserted.
The need is practical. Research peptides are made by multi-step synthesis, purified by chromatography, and dried by lyophilization. Each step introduces variability. Two vials carrying the same name from two sources can differ in sequence fidelity, in the profile of related impurities, in residual counter-ion content and in water content. A buyer who evaluates only price and catalog breadth is comparing labels. A buyer who evaluates documentation is comparing material.
This guide sets out a framework in order of how much each element tells a researcher, beginning with the evidence that is hardest to fake.
What should the identity documentation contain?
Identity comes first because purity is meaningless for the wrong molecule. The documentation for a batch should state the compound name, the batch or lot number, and the identity result, and the result should be a measured value rather than a restatement of the label.
For a peptide, the standard identity measurement is mass spectrometry: the observed molecular mass compared against the theoretical mass calculated from the sequence. A catalog reference gives the theoretical side of that comparison. Onward Aminos lists BPC-157 with formula C62H98N16O22 and molecular weight 1419.56 g/mol, and a report for that compound should show an observed mass consistent with it. Onward Aminos lists TB500 with formula C38H68N10O14 and molecular weight 868.99 g/mol, and a report for that compound has a different target to meet.
Two details sharpen the check. Observed mass in electrospray ionization usually appears as a series of multiply charged ions, so a report should either show the deconvoluted mass or list the charge states. And identity by intact mass does not confirm sequence order: two isomers with the same composition share a mass. For a short linear peptide that is rarely the deciding issue, but for a modified or longer compound, fragmentation data is the stronger evidence. Our article on confirming thermal damage analytically shows how a measured mass shift reveals a chemical change that a purity percentage alone would miss.
A purity figure is a chromatographic result: the fraction of detected signal at a chosen wavelength attributable to the main peak. Reading it responsibly means asking what the number depends on.
It depends on the method. Column chemistry, gradient shape and detection wavelength all change which impurities separate from the main peak and which co-elute under it. A figure of 99% from a short, steep gradient can be less informative than 98% from a long, shallow one, because the steep gradient may hide closely related species inside the main peak.
It depends on the integration. A report should show the actual chromatogram, not just a number, so the baseline, the main peak and the minor peaks can be inspected. A chromatogram with a flat baseline, one dominant peak and a few small peaks supports the figure. A report that offers a percentage with no trace supports nothing. The guide to HPLC purity testing goes through what a trace shows.
It depends on what the number leaves out. Area percent does not count water, counter-ions or residual solvents, so it is not the same as peptide content by weight. Our piece on matching a purity grade to an application covers why a single percentage cannot serve every assay.
What makes a certificate of analysis credible?
A certificate of analysis is only as good as its linkage to a physical batch. Credibility rests on several checkable features.
Batch specificity. The report carries a lot number that corresponds to the lot number on the vial. A generic report reused across lots, or one with no lot number, cannot be tied to the material received.
Raw data. The strongest reports attach the underlying chromatogram and mass spectrum rather than a summary table. Summary-only reports are not worthless, but they cannot be inspected.
Method statement. The report names the method: instrument type, column, mobile phase, wavelength. A named method can be reproduced or questioned.
Dates and signatory. A test date that follows the manufacture date, and a named analyst or laboratory, give the report a place in time and a responsible party.
Independence. A report from an outside laboratory carries a different weight than one produced by the seller, because the outside laboratory has no stake in the result. That does not make internal testing invalid, but it makes the independence of the testing a fact worth recording.
Retention matters after the fact. Our note on COA recordkeeping describes keeping each report with the lot it describes, so that a later result can be traced back to a specific batch.
How do storage and shipping fit into vendor evaluation?
A peptide that left the manufacturer within specification can arrive outside it. Lyophilized peptides are stable relative to solutions, but they are not inert, and they respond to heat and moisture. The article on lyophilization and peptide stability explains the mechanisms.
A vendor evaluation should therefore ask how material is held and moved. Relevant points include whether the vendor states a storage temperature for the lyophilized material, whether packaging is described, whether shipping transit time is stated, and whether the vendor addresses temperature excursions at all. A vendor that has never thought about transit conditions is unlikely to have controlled them.
Receipt is part of the same chain. A researcher should record the condition of the package on arrival, the date, and the storage placement, and should keep that note alongside the certificate. If a downstream result is ever questioned, a record that the material was received intact and stored per specification closes off a whole class of explanations.
Which red flags matter most?
Some features of a listing or a vendor predict trouble regardless of price.
No lot-level documentation. If the only evidence is a statement that the product is "high purity," the claim is unsupported.
Molecular data that does not reconcile. A listing whose formula, molecular weight and CAS number disagree with each other is a documentation problem before it is a sourcing one. A CAS number carries a check digit, so a transcription error or an invented number can fail a simple arithmetic test.
Purity figures that are uniform. A vendor reporting an identical purity figure for every compound and every lot, to the decimal, is reporting a template rather than measurements.
Claims beyond research use. Marketing language that implies a use in people rather than a laboratory material is a compliance signal about the seller's overall posture, and a reason to be cautious about everything else the seller says.
Evasion of questions. A vendor that cannot or will not supply a lot-specific report on request, or that answers a technical question with marketing copy, has answered the question.
Unrealistic breadth with no analytical depth. A very large catalog with thin documentation suggests that listing is outpacing verification.
How do vendor directories and reputation signals fit in?
Directories and ratings help with the first filter. They show who exists, what rails they accept and how many compounds they list, and they surface reputational information that would be tedious to collect individually. Treat those as screening inputs. A rating is an aggregate of other people's experience and says little about a specific batch, so it should not outweigh documentation. The sequence that holds up is: screen with directory-level information, then verify with batch-level evidence, then record both.
What does a practical evaluation checklist look like?
A compact version for a first order, applied to each candidate vendor:
- Does the listing give a name, formula, molecular weight and a CAS number that reconcile?
- Is a lot-specific report available before purchase, or on request?
- Does the report show an observed mass matching the theoretical mass?
- Is the chromatogram attached, and is the method named?
- Is the testing laboratory identified, and is it independent of the seller?
- Are storage and shipping conditions described?
- Is all language confined to laboratory research use?
A vendor that satisfies all seven has earned a trial order. A trial order is itself part of the evaluation: the researcher can run an in-house identity or purity check on the first lot and compare it to the vendor's report. Agreement between the two is the most persuasive evidence available. Disagreement is information about the supplier, and it is cheaper to learn from a single vial than from a program built on an unverified lot.
The framework does not change with the compound. A short peptide like Selank and a larger or modified molecule differ in how demanding the characterization is, but the questions asked of the supplier stay the same.
Closing note
Vendor evaluation is documentation work. The useful habits are consistent: compare claims to measured values, ask for the raw data, tie every report to a lot, record what was received, and keep the reasoning for each accept or reject decision. None of that is specific to one supplier, and all of it can be applied to Onward Aminos as readily as to any other source.
This article is provided for informational and laboratory research purposes only. The compounds discussed are research chemicals intended for in vitro and laboratory use. They are not drugs, supplements or food, and are not intended to diagnose, treat, cure or prevent any disease. Onward Aminos does not sell products intended for human use. Researchers are responsible for compliance with all applicable local, state and federal regulations. For research purposes only.
Skip to main content
